10th November 2017, Volume 130 Number 1465

Arthur Morris, Wendy McKinney, Karen Rogers, Sally Roberts, Joshua Freeman

Yeasts, mostly Candida species, can cause troublesome vulvovaginal infection. Approximately 75% of women have at least one episode of vaginal candidiasis in their lifetime.1 Some women experience recurrent disease, mainly…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Author Information

Arthur J Morris, Clinical Microbiologist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland; Wendy P McKinney, Medical Laboratory Scientist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland;
Karen Rogers, Medical Laboratory Scientist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland; Sally A Roberts, Clinical Microbiologist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland;
Joshua T Freeman, Clinical Microbiologist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland.

Correspondence

Arthur J Morris, Clinical Microbiologist, New Zealand Mycology Reference Laboratory, LabPlus, Auckland City Hospital, Auckland.

Correspondence Email

arthurm@adhb.govt.nz

Competing Interests

Nil.

References

  1. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120:1407–14.
  2. Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts; Approved Guideline – Second Edition. CLSI document M44-A2. CLSI, Wayne, PA, USA, 2009.
  3. Clinical and Laboratory Standards Institute. Zone diameter interpretive standards, corresponding minimal inhibitory concentration(MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; third informational supplement. CLSI document M44-S3. CLSI, Wayne, PA, USA, 2011.
  4. Rosco Diagnostica. Neo-Sensitabs user’s guide. Rosco Diagnostica, Taastrup, Denmark. 2013.
  5. Rosco Diagnostica. Suceptibility testing of yeasts 2011. Rosco Diagnostica, Taastrup, Denmark. 2011.
  6. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1-e50.doi:10.1093/cid/civ933
  7. Reid M. Treatment of sexually transmitted and other genital infections. BPAC Best practice Journal 2009; 20:24–9.
  8. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351:876–83.
  9. Richter SS, Galask RP, Messer SA, et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43:2155–62.
  10. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47:34–8.

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe